Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.5M Sell
212,200
-64,900
-23% -$7.49M 0.01% 945
2025
Q4
$29.2M Sell
277,100
-835,900
-75% -$78.5M 0.01% 895
2025
Q3
$93.4M Buy
1,113,000
+750,900
+207% +$61.8M 0.04% 402
2025
Q2
$28.7M Sell
362,100
-744,700
-67% -$59.2M 0.01% 791
2025
Q1
$99.3M Buy
1,106,800
+901,300
+439% +$84.2M 0.05% 325
2024
Q4
$20.4M Sell
205,500
-30,200
-13% -$3.11M 0.01% 947
2024
Q3
$26.8M Sell
235,700
-20,300
-8% -$2.41M 0.02% 799
2024
Q2
$31.7M Sell
256,000
-129,200
-34% -$16.6M 0.02% 691
2024
Q1
$50.8M Buy
385,200
+142,900
+59% +$17.6M 0.03% 473
2023
Q4
$26.4M Buy
242,300
+15,700
+7% +$1.63M 0.02% 719
2023
Q3
$23.3M Sell
226,600
-79,100
-26% -$8.53M 0.02% 709
2023
Q2
$35.3M Buy
305,700
+166,500
+120% +$18.9M 0.02% 581
2023
Q1
$14.8M Buy
139,200
+45,500
+49% +$4.91M 0.01% 958
2022
Q4
$10.4M Sell
93,700
-1,300
-1% -$133K 0.01% 1120
2022
Q3
$8.18M Buy
95,000
+3,900
+4% +$348K 0.01% 1249
2022
Q2
$8.31M Sell
91,100
-175,100
-66% -$15.5M 0.01% 1248
2022
Q1
$21.8M Sell
266,200
-342,400
-56% -$27M 0.01% 897
2021
Q4
$46.6M Buy
608,600
+370,800
+156% +$29.5M 0.03% 587
2021
Q3
$17.9M Sell
237,800
-2,300
-1% -$175K 0.01% 1068
2021
Q2
$18.7M Sell
240,100
-794,381
-77% -$59.1M 0.01% 1037
2021
Q1
$76.1M Buy
1,034,481
+536,262
+108% +$39.6M 0.05% 347
2020
Q4
$38.9M Sell
498,219
-24,104
-5% -$1.84M 0.02% 670
2020
Q3
$41.3M Sell
522,323
-542,026
-51% -$42.5M 0.03% 532
2020
Q2
$78.5M Buy
1,064,349
+4,087
+0.4% +$308K 0.06% 275
2020
Q1
$77.8M Sell
1,060,262
-154,894
-13% -$12.2M 0.07% 234
2019
Q4
$105M Buy
1,215,156
+237,477
+24% +$19.5M 0.08% 238
2019
Q3
$78.5M Sell
977,679
-173,130
-15% -$13.9M 0.06% 304
2019
Q2
$92.1M Buy
1,150,809
+173,130
+18% +$13.3M 0.07% 250
2019
Q1
$77.6M Sell
977,679
-251,206
-20% -$18.8M 0.07% 246
2018
Q4
$89.6M Buy
1,228,885
+426,851
+53% +$30.1M 0.09% 212
2018
Q3
$54.3M Sell
802,034
-361,770
-31% -$23M 0.05% 356
2018
Q2
$67.4M Sell
1,163,804
-207,818
-15% -$11.7M 0.06% 264
2018
Q1
$71.3M Buy
1,371,622
+369,105
+37% +$19.9M 0.06% 288
2017
Q4
$53.8M Buy
1,002,517
+58,374
+6% +$3.24M 0.04% 406
2017
Q3
$57.7M Buy
944,143
+191,260
+25% +$11.6M 0.05% 346
2017
Q2
$46M Buy
752,883
+21,379
+3% +$1.3M 0.04% 392
2017
Q1
$44.4M Sell
731,504
-586,251
-44% -$35.6M 0.04% 403
2016
Q4
$74M Buy
1,317,755
+378,852
+40% +$22.2M 0.07% 278
2016
Q3
$55.9M Buy
938,903
+205,093
+28% +$12M 0.05% 318
2016
Q2
$40.3M Sell
733,810
-6,183
-0.8% -$329K 0.04% 380
2016
Q1
$37.4M Sell
739,993
-190,526
-20% -$9.33M 0.04% 374
2015
Q4
$46.9M Sell
930,519
-807,903
-46% -$40.7M 0.05% 384
2015
Q3
$81.9M Buy
1,738,422
+325,613
+23% +$17.3M 0.08% 216
2015
Q2
$76.7M Buy
1,412,809
+321,841
+30% +$18.1M 0.07% 262
2015
Q1
$59.8M Sell
1,090,968
-53,658
-5% -$3.04M 0.06% 307
2014
Q4
$62M Sell
1,144,626
-93,272
-8% -$5.2M 0.06% 335
2014
Q3
$70M Sell
1,237,898
-241,354
-16% -$13.6M 0.06% 291
2014
Q2
$81.7M Buy
1,479,252
+231,922
+19% +$12.7M 0.08% 241
2014
Q1
$67.6M Buy
1,247,330
+185,287
+17% +$9.59M 0.07% 242
2013
Q4
$50.7M Buy
1,062,043
+307,064
+41% +$14M 0.05% 363
2013
Q3
$34.3M Sell
754,979
-366,695
-33% -$16.7M 0.03% 493
2013
Q2
$49.7M Buy
+1,121,674
New +$50.1M 0.05% 314

Other funds holding MRK

Citigroup's MRK Position: Q1 2026 in Review

Citigroup increased its Merck (MRK) stake by 5.4% in Q1 2026, buying an estimated $16.5M and bringing the position to 2,779,106 shares worth $334M. The position accounts for 0.14% of the portfolio, ranked #137.

Citigroup first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $824M in Q2 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Citigroup held 2,779,106 shares of Merck worth $334M as of Q1 2026.
  • Citigroup bought 142,995 Merck shares in Q1 2026, an estimated $16.5M.
  • Merck made up 0.14% of Citigroup's portfolio in Q1 2026, its #137 holding.
  • Citigroup first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Merck position peaked at $824M in Q2 2024.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.